Incidence of The Risk of Ototoxicity in Patients Undergoing Treatment with Aminoglycosides
Main Article Content
Abstract
Hearing is considered one of the fundamental human senses and is essential for maintaining an adequate quality of life. Currently, hearing loss is recognized as a serious problem and is classified as a disability, with affected individuals being susceptible to social stigmatization and isolation. This condition may even lead to increased risk of accidents, such as traffic incidents, thereby generating additional complications for the patient.
Aminoglycoside-induced ototoxicity is an irreversible adverse effect, typically presenting bilaterally and causing permanent sensory cell degeneration. Multiple mechanisms may contribute to its development during treatment with these drugs, ultimately leading to hearing loss. Although the exact mechanisms underlying this toxicity are not fully understood, reports of this severe adverse effect are increasing. Despite this, aminoglycosides continue to be widely used worldwide due to their low cost, availability, and effectiveness.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Sagit, M., Korkmaz, F., Gürgen, S., Kaya, M., Akcadag, A. and Ozcan, I. (2014). The protective role of thymoquinone in the prevention of gentamicin ototoxicity. American Journal of Otolaryngology, 35(5), pp.603-609.
II. Papadakis a. maxine, stephen j. mcphee. Current. cmdt. Medical diagnosis and treatment. Elsevier. mcgraw-hill. 2015.
III. Mohamed N. El-barbary, Rania I.H. Ismail, Adel A.A. Ibrahim. Gentamicin extended interval regimen and ototoxicity in neonates. M.N. El-barbary et al. / International Journal of Pediatric Otorhinolaryngology 79 (2015) 1294–1298.
IV. Abbas, Leila, and Marcelo N. Rivolta. "Aminoglycoside Ototoxicity and Hair Cell Ablation in the Adult Gerbil: A Simple Model to Study Hair Cell Loss and Regeneration". Hearing Research 325 (2015): 12-26. Web.
V. Dong, Yaodong et al. "Nahs Protects Cochlear Hair Cells From Gentamicin-Induced Ototoxicity By Inhibiting The Mitochondrial Apoptosis Pathway". PLOS ONE 10.8 (2015): e0136051. Web.
VI. J.-W. Koo, L. Quintanilla-Dieck, M. Jiang, J. Liu, Z. D. Urdang, J.J. Allensworth, et. Al. Endotoxemia-mediated inflammation potentiates aminoglycoside-induced ototoxicity. Sci Transl Med. 2015 July 29; 7(298): 298ra118.
VII. Sogebi O, Adefuye B, Adebola S , Oladeji S , Adedeji T. Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy. O.A. Sogebi et al. / Auris Nasus Larynx xxx (2016) xxx–xxx.
VIII. BlunstonM, Yonovitz A, Woodahl E, Smolensky M. Gentamicin-Induced Ototoxicity and Nephrotoxicity Vary with Circadian Time of Treatment and Entail Separate Mechanisms. Chronobiol Int. 2015; 32(9): 1223–1232.
IX. He, Jing-chun et al. "Streptomycin Ototoxicity In Rat Cochlear Organotypic Cultures". Cell Biochemistry and Biophysics 71.2 (2014): 851-856. Web. 26 Apr. 2017.
X. Adebolajo A. Adeyemo, Odunayo Oluwatosin, and Olayemi O. Omotade. Study of streptomycin-induced ototoxicity: protocol for a longitudinal study. Springerplus. 2016; 5(1): 758.
XI. Ghada Al-Malky, Sally J. Dawson, Tony Sirimanna, Emmanouil Bagkeris, Ranjan Suri. High-frequency audiometry reveals high prevalence of aminoglycoside ototoxicity in children with cystic fibrosis. Journal of Cystic Fibrosis 14 (2015) 248– 254.
XII. J. L.Llorente pendas, C. A. Álvarez Marcos, F. J. Nuñez Batalla. Otorrinolaringología. 1ra ed. México. Panamericana. 2011.
XIII. Anil k. Lalwani. Otorrinolaringología. Current diagnosis & treatment otolaryngology--head and neck surgery third edition. 3th ed. USA. McGraw-Hill. 2012.